Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 155

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 155
---
uromodulation661 205 866 616 191 807 MedSurg3,478 1,537 5,015 2,941 1,433 4,373 Interventional Cardiology Therapies740 1,373 2,114 608 1,370 1,977 Watchman1,306 117 1,423 996 107 1,103 Cardiac Rhythm Management1,066 679 1,746 1,054 658 1,713 Electrophysiology1,706 729 2,435 795 460 1,255 Cardiology4,818 2,899 7,717 3,452 2,595 6,048 Peripheral Interventions1,183 873 2,056 924 841 1,765 Cardiovascular6,002 3,772 9,773 4,377 3,436 7,813 Total Net Sales$9,479 $5,309 $14,788 $7,317 $4,869 $12,186 Refer to Note J – Segment Reporting for information on our reportable segments.Three Months Ended September 30,Nine Months Ended September 30,Geographic Regions2025202420252024U.S.$3,294 $2,593 $9,479 $7,317 Europe, Middle East and Africa793 773 2,518 2,398 Asia-Pacific802 684 2,292 2,002 Latin America and Canada175 159 499 469 Total Net Sales$5,065 $4,209 $14,788 $12,186 Emerging Markets(1)$765 $684 $2,214 $2,012 (1) Our Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.Deferred RevenueContract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $668 million as of September 30, 2025 and $635 million as of December 31, 2024. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service